Iradimed
Through the investors’ lenses
Each of these investors has said in public what they look at before buying. Click a name to see how this company measures up — a tick where it passes one of their tests, a cross where it does not.
Warren Buffett 3/3
| Measure | IRMD | Checked against | |
|---|---|---|---|
| Owner earnings | $15.88m | positive | ✓ |
| Return on equity | 23.8% | median 11.7% | ✓ |
| Debt to equity | — | median 0.79x | — |
| Operating margin | 31.2% | median 15.0% | ✓ |
Passes 3 of 3. To be clear: Warren Buffett has never said anything about Iradimed. These are the company’s own figures put through the tests he described. What he looks at, and why →
Terry Smith 1/2
| Measure | IRMD | Checked against | |
|---|---|---|---|
| Return on capital employed | — | median 10.1% | — |
| Cash conversion | 1.11x | median 1.78x | ✗ |
| Operating margin | 31.2% | median 15.0% | ✓ |
| Debt to equity | — | median 0.79x | — |
Passes 1 of 2. To be clear: Terry Smith has never said anything about Iradimed. These are the company’s own figures put through the tests he described. What he looks at, and why →
Charlie Munger 2/2
| Measure | IRMD | Checked against | |
|---|---|---|---|
| Return on capital employed | — | median 10.1% | — |
| Return on equity | 23.8% | median 11.7% | ✓ |
| Operating margin | 31.2% | median 15.0% | ✓ |
Passes 2 of 2. To be clear: Charlie Munger has never said anything about Iradimed. These are the company’s own figures put through the tests he described. What he looks at, and why →
Chuck Akre 2/3
| Measure | IRMD | Checked against | |
|---|---|---|---|
| Return on equity | 23.8% | median 11.7% | ✓ |
| Debt to equity | — | median 0.79x | — |
| Cash conversion | 1.11x | median 1.78x | ✗ |
| Return on equity, sustained | 8 of 10 | 8 of 10 above median | ✓ |
Passes 2 of 3. To be clear: Chuck Akre has never said anything about Iradimed. These are the company’s own figures put through the tests he described. What he looks at, and why →
Philip Fisher 3/3
| Measure | IRMD | Checked against | |
|---|---|---|---|
| Operating margin | 31.2% | median 15.0% | ✓ |
| Net margin | 26.8% | median 10.2% | ✓ |
| Return on capital employed | — | median 10.1% | — |
| Operating margin, held or improving | 31.2% | 10-yr median 23.5% | ✓ |
Passes 3 of 3. To be clear: Philip Fisher has never said anything about Iradimed. These are the company’s own figures put through the tests he described. What he looks at, and why →
Walter Schloss 1/1
| Measure | IRMD | Checked against | |
|---|---|---|---|
| Current ratio | 7.98x | median 1.25x | ✓ |
| Debt to equity | — | median 0.79x | — |
Passes 1 of 1. To be clear: Walter Schloss has never said anything about Iradimed. These are the company’s own figures put through the tests he described. What he looks at, and why →
Benjamin Graham 2/2
| Measure | IRMD | Checked against | |
|---|---|---|---|
| Current ratio | 7.98x | 2.00x published | ✓ |
| Long-term debt to working capital | — | 1.00x published | — |
| Positive earnings, ten years running | 10 yrs | 10 published | ✓ |
Passes 2 of 2. To be clear: Benjamin Graham has never said anything about Iradimed. These are the company’s own figures put through the tests he described. What he looks at, and why →
Peter Lynch 1/1
| Measure | IRMD | Checked against | |
|---|---|---|---|
| Debt to equity | — | median 0.79x | — |
| Net margin | 26.8% | median 10.2% | ✓ |
Passes 1 of 1. To be clear: Peter Lynch has never said anything about Iradimed. These are the company’s own figures put through the tests he described. What he looks at, and why →
| Basis | Payout | Why |
|---|---|---|
| GAAP earnings | 66.9% | whyThe figure most screeners publish. |
| Operating cash flow | 60.3% | whyBefore capital spending. |
| Free cash flow | 87.5% | whyAfter maintaining the business. |
Spread between highest and lowest: 27.2 percentage points. Same filings, different denominators.
Coverage rating 39 / 100 — Strained. ? Peer standing 5/50Direction 30/30Stability 3/20
Free cash flow payout, last 4 years
| Fiscal year | Payout |
|---|---|
| 2025-12-31 | 87.5% |
| 2024-12-31 | 77.6% |
| 2023-12-31 | 219.5% |
| 2022-12-31 | 139.7% |
11% of the 38 health care here pay out more — at the demanding end.
The arithmetic
- GAAP earnings — dividends declared per share $1.17 ÷ diluted EPS $1.75
- Operating cash flow — dividends paid $15.0m ÷ operating cash flow $24.9m
- Free cash flow — dividends paid $15.0m ÷ (operating cash flow $24.9m − capex $7.76m)
Where the figures came from
- 10-K filed 2026-03-06 · accession 0001104659-26-024691
All public at sec.gov — you should not have to take our word for it.
Caveats on this company
- DPS derived from dividends paid ($1.17); no per-share tag filed
Computed straight from SEC XBRL. A number that looks wrong to you is more useful to us than agreement — tell us.
What the free cash flow payout ratio measures, and where every company here sits on it.
Also on: rated strained · when it files.
When this changes
Every figure above is recomputed whenever Iradimed files. The monthly letter carries what filed, what moved, and one finding computed across every company here.